Health Care·Biotechnology·$79.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.78 | N/A | +68.56% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.78 | N/A | +68.56% |
| Revenue | N/A | N/A | N/A |
Tone: Confident
Management expressed confidence in their financial performance, particularly in EPS. They emphasized their commitment to pipeline development.
We are pleased with our EPS performance this quarter.
Our focus remains on advancing our pipeline.
Regeneron's strong EPS performance, significantly above expectations, contributed to a 7.05% increase in stock price. The positive surprise indicates effective cost management and operational efficiency. However, the lack of revenue data and guidance leaves some uncertainty about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PFIZER INC
Apr 30, 2013